$CYRX News

Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Targets On Growth Trends

BTIG Maintains Buy on CryoPort, Raises Price Target to $25

Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026

Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

Cryoport’s IntegriCell Cryopreservation Services Selected By Verismo Therapeutics To Support SynKIR-110 And SynKIR-310 Multi-Chain KIR-CAR Programs

Cryoport (CYRX) Stock Fair Value Rises After Analysts Revisit Bioservices Outlook

Craig-Hallum Maintains Buy on CryoPort, Raises Price Target to $20

Keybanc Maintains Overweight on CryoPort, Raises Price Target to $17

Guggenheim Maintains Buy on CryoPort, Raises Price Target to $12

Needham Maintains Buy on CryoPort, Raises Price Target to $15

BTIG Maintains Buy on CryoPort, Raises Price Target to $17

Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript

Cryoport Inc (NASDAQ:CYRX) Reports Q1 2026 Revenue Beat Amid Wider Net Loss and Cautious Full-Year Outlook

Cryoport, Inc. 2026 Q1 - Results - Earnings Call Presentation

Cryoport Posts Revenue Beat In Q1 As Clinical Trial Support Hits All-Time High — 'A Strong Start To 2026'

CryoPort Raises FY2026 Sales Guidance from $190.000M-$194.000M to $192.000M-$196.000M vs $191.834M Est

CryoPort Q1 Adj. EPS $(0.25) Misses $(0.22) Estimate, Sales $47.800M Beat $44.862M Estimate

Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven

Craig-Hallum Initiates Coverage On CryoPort with Buy Rating, Announces Price Target of $15

Needham Maintains Buy on CryoPort, Raises Price Target to $13